欧州連合 - イタリア語 - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

欧州連合 - イタリア語 - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - mieloma multiplo - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combinazione con bortezomib, talidomide e desametasone per il trattamento di pazienti adulti con nuova diagnosi di mieloma multiplo che sono eleggibili per il trapianto di cellule staminali autologhe. in combinazione con lenalidomide e desametasone, o bortezomib e desametasone per il trattamento di pazienti adulti con mieloma multiplo che hanno ricevuto almeno una precedente terapia. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. come monoterapia per il trattamento di pazienti adulti con recidivo e refrattario mieloma multiplo, la cui prima terapia incluso un inibitore del proteasoma e un agente immunomodulante e che hanno dimostrato la progressione della malattia, l'ultima terapia. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

欧州連合 - イタリア語 - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma multiplo - agenti antineoplastici - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, lactosum 20.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.204 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 5.0 mg, lactosum 40.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.408 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, lactosum 60.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.612 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 10.0 mg, lactosum 80.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.816 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 15.0 mg, lactosum 120.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.224 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 20.0 mg, lactosum 160.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 1.632 mg, magnesii stearas, kapselhülle: gelatina, e 132, titanii dioxidum, e 172 (flavum), drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

スイス - イタリア語 - Swissmedic (Swiss Agency for Therapeutic Products)

devatis ag - lenalidomidum - capsule rigide - lenalidomidum 25.0 mg, lactosum 200.0 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 2.04 mg, magnesii stearas, kapselhülle: gelatina, titanii dioxidum, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika